Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
- Trial name
- NCT00885352
- Testing
- Sitagliptin, Pioglitazone, Metformin
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD3 (NCT03242252)
- Testing
- Sotagliflozin
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 787 people
- Sponsor
- Lexicon Pharmaceuticals
Type-2 Diabetes Mellitus
Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider…
- Trial name
- NCT01766778
- Testing
- LAF237 (vildagliptin), Metformin
- Where
- 4 sites in Hong Kong
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based…
- Trial name
- NCT00437489
- Testing
- Inhaled Human Insulin (Exubera)
- Where
- 9 sites in Hong Kong, Pakistan and 2 more
- Volunteers
- 49 people
- Sponsor
- Pfizer
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Type II Diabetes
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
- Trial name
- NCT02429258
- Testing
- Farxiga, Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
This study evaluate DRBP108 in the treatment of type 2 diabetes mellitus. The patients were randomly allocated to four groups: 50 mg, 100 mg, 200 mg and placebo group.
- Trial name
- NCT04124484
- Where
- China
- Volunteers
- 276 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
This is a multicenter, randomized, double-blind, placebo- and active comparator-controlled phase 2/3 study of three dose levels of MBX-102 (200, 400, 600 mg) given orally to patients with type 2 diabetes receiving concomitant…
- Trial name
- NCT00353587
- Testing
- MBX-102, Actos
- Where
- 67 sites in United States, Argentina and 2 more
- Volunteers
- 396 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT03159052
- Testing
- SHR3824
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants…
- Trial name
- AUTONOMY (NCT01215955)
- Testing
- Insulin lispro, Glargine
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
PROTEINURIA, Hypertension
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
- Conditions
- PROTEINURIA, Hypertension, Type 2 Diabetes
- Trial name
- NCT00241085
- Testing
- valsartan
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition…
- Trial name
- NCT04531462
- Testing
- Empagliflozin
- Where
- 18 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.
The purpose of this study is to determine the metabolic and cardiovascular effects of pioglitazone, once daily (QD), and insulin combination therapy in subjects with Type 2 Diabetes and Renal Failure.
- Trial name
- PIOren (NCT00770640)
- Testing
- Pioglitazone and insulin, Insulin
- Where
- 9 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Type 2 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications…
- Trial name
- NCT03338010
- Testing
- LY2963016, Lantus®
- Where
- 32 sites in China
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes
Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS during 4 week treatment duration
- Trial name
- NCT02183415
- Testing
- BI 1356 BS, low dose, BI 1356 BS, medium dose, BI 1356 BS, high dose
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone.
- Trial name
- NCT01516476
- Testing
- RO6807952, liraglutide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone
The purpose of this study is to evaluate the safety and efficacy of long-term use of pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients with type 2 diabetes mellitus who respond poorly to…
- Trial name
- NCT02098746
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 294 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.